David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm.
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm. Reardon says rindopepimut is the first immunotherapy to ever show a survival benefit in glioblastoma and hopes a randomized phase III double blind trial with a placebo control arm will allow the drug to make bigger strides in the treatment of the malignancy.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More